ZYME Zymeworks Inc.
Zymeworks Inc. (ZYME) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $1.3M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Galbraith Kenneth | Chair & CEO | Sell | 30,424 | $22.67 | $689.8K | 226,842 −11.8% of holding | |
| Moore Paul Andrew | Chief Scientific Officer | Sell | 9,560 | $22.67 | $216.8K | 48,497 −16.5% of holding | |
| Smith Jeffrey T L | EVP & Chief Medical Officer | Sell | 9,310 | $22.67 | $211.1K | 26,708 −25.8% of holding | |
| Hollywood Mark | EVP & Chief Operating Officer | Sell | 6,120 | $22.67 | $138.8K | 132,913 −4.4% of holding | |
| Galbraith Kenneth 2 fills | Chair & CEO | Sell | 54,343 | $25.10 | $1.4M | 193,266 −21.9% of holding | |
| Moore Paul Andrew 2 fills | Chief Scientific Officer | Sell | 20,110 | $25.10 | $504.7K | 40,391 −33.2% of holding | |
| Smith Jeffrey T L | EVP & Chief Medical Officer | Sell | 10,538 | $25.10 | $264.5K | 18,352 −36.5% of holding | |
| Galbraith Kenneth | Chair & CEO | Sell | 47,528 | $27.02 | $1.3M | 133,275 −26.3% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.